Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) shares traded down 21.1% on Thursday . The company traded as low as C$1.50 and last traded at C$1.50. 300 shares were traded during trading, a decline of 95% from the average daily volume of 6,289 shares. The stock had previously closed at C$1.90.
Genscript Biotech Stock Down 21.1%
The business’s 50 day moving average price is C$1.64 and its 200-day moving average price is C$1.64.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Read More
- Five stocks we like better than Genscript Biotech
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
